GGCX

Across TCGA pan-cancer cohorts, GGCX mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GGCX data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GGCX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GGCX expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where GGCX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.263	0.555	<.001	62	view →
COAD	DFS	Tertile	All	0.884	1.000	.023	24	view →
LUAD	OS	Tertile	III,IV	0.838	0.332	.015	10	view →
UCEC	DFS	Quartile	All	0.872	1.000	.032	4	view →
CCRCC	DFS	Median	III,IV	0.428	0.725	.028	2	view →
GBM	DFS	Tertile	All	0.276	0.529	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GGCX–PDAC (DFS)

Open the PDAC breakdown →